Lucerna has received a 1 year $225K SBIR Phase I grant from the National Institute of Allergy and Infectious Diseases to develop new high-throughput screening (HTS)…
Lucerna has received a 1 year $225K SBIR Phase I grant from the National Institute of Allergy and Infectious Diseases to develop new high-throughput screening (HTS)…